1615 related articles for article (PubMed ID: 10965921)
21. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
Evans CE; Mylchreest S; Andrew JG
BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
[TBL] [Abstract][Full Text] [Related]
22. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
23. A novel molecular mechanism modulating osteoclast differentiation and function.
Yasuda H; Shima N; Nakagawa N; Yamaguchi K; Kinosaki M; Goto M; Mochizuki SI; Tsuda E; Morinaga T; Udagawa N; Takahashi N; Suda T; Higashio K
Bone; 1999 Jul; 25(1):109-13. PubMed ID: 10423033
[TBL] [Abstract][Full Text] [Related]
24. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
Swanson C; Lorentzon M; Conaway HH; Lerner UH
Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
[TBL] [Abstract][Full Text] [Related]
25. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
Lee SK; Lorenzo JA
Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
[TBL] [Abstract][Full Text] [Related]
26. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
Palmqvist P; Persson E; Conaway HH; Lerner UH
J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
[TBL] [Abstract][Full Text] [Related]
27. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
Huang L; Xu J; Wood DJ; Zheng MH
Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
[TBL] [Abstract][Full Text] [Related]
28. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
[TBL] [Abstract][Full Text] [Related]
29. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
[TBL] [Abstract][Full Text] [Related]
30. 1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts.
Lee SK; Kalinowski J; Jastrzebski S; Lorenzo JA
J Immunol; 2002 Sep; 169(5):2374-80. PubMed ID: 12193704
[TBL] [Abstract][Full Text] [Related]
31. Runx-2 is not essential for the vitamin D-regulated expression of RANKL and osteoprotegerin in osteoblastic cells.
Notoya M; Otsuka E; Yamaguchi A; Hagiwara H
Biochem Biophys Res Commun; 2004 Nov; 324(2):655-60. PubMed ID: 15474477
[TBL] [Abstract][Full Text] [Related]
32. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
[TBL] [Abstract][Full Text] [Related]
33. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
[TBL] [Abstract][Full Text] [Related]
34. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
[TBL] [Abstract][Full Text] [Related]
35. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242
[TBL] [Abstract][Full Text] [Related]
36. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Kaji H; Kanatani M; Sugimoto T; Chihara K
Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
[TBL] [Abstract][Full Text] [Related]
37. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
38. High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors.
Shin MM; Kim YH; Kim SN; Kim GS; Baek JH
Exp Mol Med; 2003 Jun; 35(3):167-74. PubMed ID: 12858015
[TBL] [Abstract][Full Text] [Related]
39. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs.
Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K
J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941
[TBL] [Abstract][Full Text] [Related]
40. Dental cells express factors that regulate bone resorption.
Rani CS; MacDougall M
Mol Cell Biol Res Commun; 2000 Mar; 3(3):145-52. PubMed ID: 10860862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]